WO2006033700A3 - Her2 antibody composition - Google Patents
Her2 antibody composition Download PDFInfo
- Publication number
- WO2006033700A3 WO2006033700A3 PCT/US2005/025084 US2005025084W WO2006033700A3 WO 2006033700 A3 WO2006033700 A3 WO 2006033700A3 US 2005025084 W US2005025084 W US 2005025084W WO 2006033700 A3 WO2006033700 A3 WO 2006033700A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- her2 antibody
- composition
- antibody composition
- disclosed
- her2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167021573A KR20160096228A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
PL05818254T PL1771482T3 (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
SI200531907T SI1771482T1 (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020197008923A KR20190035967A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
CA2574821A CA2574821C (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
NZ552580A NZ552580A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
EP05818254.4A EP1771482B1 (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
MX2007000723A MX2007000723A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition. |
ES05818254.4T ES2521140T3 (en) | 2004-07-22 | 2005-07-15 | HER2 antibody composition |
KR1020187022854A KR20180091967A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
JP2007522579A JP2008507520A (en) | 2004-07-22 | 2005-07-15 | HER2 antibody composition |
UAA200701640A UA90480C2 (en) | 2004-07-22 | 2005-07-15 | HER2 antibody composition exhibiting anticancer activity |
CN2005800319054A CN101023100B (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
RSP20140611 RS53594B1 (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020187000071A KR20180004850A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020197032521A KR20190126461A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020157009058A KR20150043558A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020157034266A KR20150140417A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
DK05818254.4T DK1771482T3 (en) | 2004-07-22 | 2005-07-15 | HER2 antibody composition |
KR1020147003441A KR20140032004A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
KR1020137015103A KR20130079648A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
AU2005287404A AU2005287404B2 (en) | 2004-07-22 | 2005-07-15 | HER2 antibody composition |
BRPI0513681-4A BRPI0513681A (en) | 2004-07-22 | 2005-07-15 | compositions comprising her2 antibody, method, pharmaceutical formulations, polypeptide, antibody and cancer treatment method |
KR1020177012110A KR20170054551A (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
IL180608A IL180608A0 (en) | 2004-07-22 | 2007-01-09 | Her2 antibody composition |
TNP2007000020A TNSN07020A1 (en) | 2004-07-22 | 2007-01-19 | Her2 antibody composition |
NO20070989A NO341293B1 (en) | 2004-07-22 | 2007-02-21 | HER2 antibody composition, the antibody, a pharmaceutical formulation thereof, and the use of the composition for the manufacture of a medicament for the treatment of HER2-expressing cancer. |
HK07110819.1A HK1102599A1 (en) | 2004-07-22 | 2007-10-05 | Her2 antibody composition her2 |
HRP20141111TT HRP20141111T1 (en) | 2004-07-22 | 2014-11-17 | Her2 antibody composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59020204P | 2004-07-22 | 2004-07-22 | |
US50/590,202 | 2004-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006033700A2 WO2006033700A2 (en) | 2006-03-30 |
WO2006033700A3 true WO2006033700A3 (en) | 2006-09-21 |
Family
ID=36090425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/025084 WO2006033700A2 (en) | 2004-07-22 | 2005-07-15 | Her2 antibody composition |
Country Status (37)
Country | Link |
---|---|
US (3) | US7560111B2 (en) |
EP (1) | EP1771482B1 (en) |
JP (7) | JP2008507520A (en) |
KR (14) | KR20160096228A (en) |
CN (1) | CN101023100B (en) |
AR (2) | AR050353A1 (en) |
AU (1) | AU2005287404B2 (en) |
BR (1) | BRPI0513681A (en) |
CA (1) | CA2574821C (en) |
CO (1) | CO5720212A1 (en) |
CR (1) | CR8932A (en) |
DK (1) | DK1771482T3 (en) |
EC (1) | ECSP077261A (en) |
ES (1) | ES2521140T3 (en) |
GT (1) | GT200500199A (en) |
HK (1) | HK1102599A1 (en) |
HR (1) | HRP20141111T1 (en) |
IL (1) | IL180608A0 (en) |
JO (1) | JO2984B1 (en) |
MA (1) | MA28784B1 (en) |
MX (1) | MX2007000723A (en) |
MY (1) | MY169272A (en) |
NO (1) | NO341293B1 (en) |
NZ (1) | NZ552580A (en) |
PA (1) | PA8639701A1 (en) |
PE (1) | PE20060552A1 (en) |
PL (1) | PL1771482T3 (en) |
PT (1) | PT1771482E (en) |
RS (1) | RS53594B1 (en) |
RU (1) | RU2361880C2 (en) |
SI (1) | SI1771482T1 (en) |
SV (1) | SV2006002174A (en) |
TN (1) | TNSN07020A1 (en) |
TW (1) | TWI369992B (en) |
UA (1) | UA90480C2 (en) |
WO (1) | WO2006033700A2 (en) |
ZA (1) | ZA200701234B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
US9255149B2 (en) | 2008-05-02 | 2016-02-09 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Cytotoxic immunoglobulin |
Families Citing this family (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
SV2006002143A (en) * | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
KR20160096228A (en) * | 2004-07-22 | 2016-08-12 | 제넨테크, 인크. | Her2 antibody composition |
JO3000B1 (en) * | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
ATE425186T1 (en) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES MODIFIED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE AREAS DETERMINING COMPLEMENTARITY |
EP3698807A1 (en) * | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
AU2006216732C1 (en) * | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
MX2007009963A (en) * | 2005-02-24 | 2007-09-26 | Amgen Inc | Epidermal growth factor receptor mutations. |
PE20070207A1 (en) | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
SI2573114T1 (en) * | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2007090794A1 (en) * | 2006-02-10 | 2007-08-16 | Nerviano Medical Sciences S.R.L. | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
JP2009529331A (en) * | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | Identification and engineering modification of antibodies having mutated heavy chains and methods of use thereof |
WO2008105886A2 (en) * | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
LT2029173T (en) | 2006-06-26 | 2016-11-10 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
JP5602625B2 (en) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding substance display |
CA2693799A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
RU2370280C2 (en) * | 2007-10-08 | 2009-10-20 | Институт физико-химической биологии им. А.Н.Белозерского | METHOD OF HER2/neu ONCOGENE ANTIBODY SUPERPRODUCTION IN PLANT |
TWI472339B (en) * | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
ES2654937T3 (en) | 2008-04-02 | 2018-02-15 | Macrogenics, Inc. | Specific antibodies for the BCR complex and procedures for their use |
WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
JP2010006705A (en) * | 2008-06-13 | 2010-01-14 | Atlas Antibodies Ab | Her2 subset |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
JP5986745B2 (en) | 2008-07-15 | 2016-09-06 | アカデミア シニカAcademia Sinica | Glycan arrays on PTFE-like aluminum-coated glass slides and related methods |
CA2751730A1 (en) * | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris |
US20110313137A1 (en) * | 2009-02-25 | 2011-12-22 | Dongxing Zha | Her2 antibody compositions |
US8401035B2 (en) * | 2009-07-14 | 2013-03-19 | Level 3 Communications, Llc | One way SRS information transmission method |
US8064431B2 (en) * | 2009-07-14 | 2011-11-22 | Level 3 Communications, Llc | One way information transmission method |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
EP2507381A4 (en) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | Multispecific antibodies, antibody analogs, compositions, and methods |
EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
EP2558501B1 (en) | 2010-04-15 | 2016-09-07 | Alper Biotech, Llc | Monoclonal antibodies against her2 antigens, and uses therefor |
CA2835489C (en) | 2010-05-10 | 2018-03-06 | Chi-Huey Wong | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
AU2011257121A1 (en) | 2010-05-27 | 2013-01-10 | Genmab A/S | Monoclonal antibodies against HER2 |
CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
US9217039B2 (en) | 2010-11-01 | 2015-12-22 | Symphogen A/S | Anti-HER3 antibodies and compositions |
US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
CN103796677B (en) | 2011-04-20 | 2019-08-16 | 健玛保 | For the bispecific antibody of HER2 and CD3 |
CN103857700A (en) | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | Tandem FC bispecific antibodies |
DK2766040T3 (en) | 2011-10-14 | 2019-07-22 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
RU2627185C1 (en) * | 2012-03-16 | 2017-08-03 | Коваген Аг | New binding molecules with anti-tumour activity |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
ES2546105T3 (en) | 2012-04-17 | 2015-09-18 | Arsanis Biosciences Gmbh | Cross-reactive antibody against Staphylococcus aureus |
ES2431914B2 (en) * | 2012-04-27 | 2014-07-24 | Universidad De Cádiz | ANTI-HER2 human monoclonal antibody |
MX2014014162A (en) * | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Multispecific antibodies. |
EP2858648B1 (en) | 2012-06-07 | 2018-08-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
WO2014015137A2 (en) * | 2012-07-18 | 2014-01-23 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
WO2014028446A1 (en) | 2012-08-13 | 2014-02-20 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
WO2014031762A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
HUE045435T2 (en) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2014070957A1 (en) | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
MX363188B (en) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identification of patients in need of pd-l1 inhibitor cotherapy. |
KR20210088741A (en) * | 2012-12-13 | 2021-07-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Dna antibody constructs and method of using same |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
BR112015025347A2 (en) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment |
AR095863A1 (en) * | 2013-04-16 | 2015-11-18 | Genentech Inc | VARIATIONS OF PERTUZUMAB, ITS ASSESSMENT, METHOD OF TREATMENT, METHOD OF PREPARATION AND ARTICLE OF MANUFACTURE |
EP2994164B1 (en) | 2013-05-08 | 2020-08-05 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
KR101453462B1 (en) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Antibodies Capable of Binding Specifically to HER2 |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
WO2015073721A1 (en) | 2013-11-13 | 2015-05-21 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
KR101854443B1 (en) | 2013-11-19 | 2018-06-15 | 레메젠 리미티드 | Anti-her2 antibody and conjugate thereof |
MX2016006572A (en) | 2013-11-27 | 2016-12-09 | Zymeworks Inc | Bispecific antigen-binding constructs targeting her2. |
JP6510532B2 (en) | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific HER2 antibodies and methods of use |
AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3973995A1 (en) * | 2014-01-31 | 2022-03-30 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
EP3502134B1 (en) | 2014-03-11 | 2020-12-16 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
JP6856378B2 (en) | 2014-03-11 | 2021-04-07 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | A protein containing the Shiga toxin A subunit effector region and the cell-targeted immunoglobulin-type binding region located proximal to the amino terminus. |
CA2943242A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
TWI687428B (en) | 2014-03-27 | 2020-03-11 | 中央研究院 | Reactive labelling compounds and uses thereof |
JP6612738B2 (en) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | Anti-HER2 antibody-drug conjugate |
EP3134440A1 (en) | 2014-04-25 | 2017-03-01 | F. Hoffmann-La Roche AG | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
CN106573971A (en) | 2014-05-27 | 2017-04-19 | 中央研究院 | Anti-CD20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
EP3149161B1 (en) | 2014-05-27 | 2021-07-28 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
US9968579B2 (en) | 2014-07-17 | 2018-05-15 | Beth Isreal Deaconess Medical Center, Inc. | ATRA for modulating Pin1 activity and stability |
KR101608301B1 (en) | 2014-08-22 | 2016-04-12 | 앱클론(주) | Antibodies Capable of Binding Specifically to HER2 |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EA201790545A1 (en) * | 2014-09-12 | 2017-07-31 | Дженентек, Инк. | ANTIBODIES AND IMMUNOCONJUGATES AGAINST HER2 |
JP6730261B2 (en) | 2014-09-17 | 2020-07-29 | ジェネンテック, インコーポレイテッド | Immune complex containing anti-HER2 antibody |
CN104225594B (en) * | 2014-09-23 | 2016-03-23 | 合肥瀚科迈博生物技术有限公司 | Anti-HER 2 humanized antibody and relevant anti-tumor compositions thereof |
CN107427566B (en) | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | DNA antibody constructs and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
EP3248005B1 (en) | 2015-01-24 | 2020-12-09 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CN105985435B (en) * | 2015-01-30 | 2019-10-15 | 嘉和生物药业有限公司 | The mutant antibodies and its encoding gene of full source of people HER2 antibody and application |
WO2016145186A1 (en) | 2015-03-12 | 2016-09-15 | Beth Israel Deaconess Medical Center, Inc. | Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
EP3294772A4 (en) | 2015-05-13 | 2019-05-01 | Zymeworks Inc. | Antigen-binding constructs targeting her2 |
EP3302551A2 (en) | 2015-05-30 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer |
CN107849096B (en) | 2015-05-30 | 2022-05-24 | 分子模板公司 | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them |
TW201717935A (en) | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | Compositions and methods for treating cancer |
KR20180021723A (en) | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | Method for selectively manufacturing antibody-drug conjugate |
EP3325510A2 (en) | 2015-07-26 | 2018-05-30 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
CN105132357B (en) * | 2015-07-29 | 2019-12-06 | 苏州诺普再生医学有限公司 | serum-free culture system for epidermal cell culture |
MX2018002226A (en) | 2015-08-28 | 2018-03-23 | Amunix Operating Inc | Chimeric polypeptide assembly and methods of making and using the same. |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
WO2017079694A2 (en) * | 2015-11-04 | 2017-05-11 | Priceman Saul J | Chimeric antigen receptors targeting her2 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
TWI727380B (en) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
TW201808978A (en) | 2016-03-08 | 2018-03-16 | 中央研究院 | Methods for modular synthesis of N-glycans and arrays thereof |
RU2648161C2 (en) * | 2016-04-01 | 2018-03-22 | Юрий Леонидович Дорохов | Method of obtaining the antibody, which specifically binds the domain of the her2/neu excellular part of the her2/neu oncoprotein, in the plant, the antibody, which is obtained by means of this method and its application |
MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
KR101923624B1 (en) | 2016-07-28 | 2018-11-30 | 고려대학교 산학협력단 | AGTR1 aptamer-anticancer drug complex for cancer cell chemotherapy |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
CN109862919A (en) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | The therapeutic agent that antibody-drug conjugates combined immunization mediates |
JP2019532999A (en) | 2016-11-04 | 2019-11-14 | ジェネンテック, インコーポレイテッド | Treatment of HER2-positive breast cancer |
KR101923641B1 (en) | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | Anti-HER3 antibody and composition for preventing or treating cancer comprising the same |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
WO2018110515A1 (en) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
CN110099926A (en) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | The treatment of advanced stage HER2 expressivity cancer |
MX2019008059A (en) | 2017-01-17 | 2019-12-11 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate. |
RU2750821C2 (en) | 2017-01-17 | 2021-07-05 | Дженентек, Инк. | Anti-her2 antibody drugs for subcutaneous injection |
US11377497B2 (en) | 2017-01-23 | 2022-07-05 | Suzhou Alphamab Co., Ltd. | PD-L1 binding polypeptide or composite |
WO2018140427A1 (en) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
EP3579848A4 (en) | 2017-02-08 | 2021-03-03 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
AU2018220736A1 (en) * | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
FI3589661T3 (en) | 2017-03-02 | 2024-01-31 | Genentech Inc | Adjuvant treatment of her2-positive breast cancer |
US11207420B2 (en) | 2017-04-19 | 2021-12-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Cytotoxin and conjugate, uses of same and preparation method therefor |
CN110536969A (en) | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | ERBB2/HER2 mutation in cross-film or nearly film domain |
AR111651A1 (en) | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
TWI794230B (en) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof |
JP2020520923A (en) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | Methods for treating cancer |
CN111051330A (en) | 2017-08-31 | 2020-04-21 | 第一三共株式会社 | Improved preparation method of antibody-drug conjugate |
US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
CN111132998B (en) | 2017-09-25 | 2024-01-30 | 苏州丁孚靶点生物技术有限公司 | Methods and compositions for cancer treatment |
CN111655732B (en) | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | anti-HER 2 antibodies or antigen binding fragments thereof and chimeric antigen receptors comprising same |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CA3080236A1 (en) | 2017-12-15 | 2019-06-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
CN112368012A (en) | 2018-02-08 | 2021-02-12 | 蜻蜓疗法股份有限公司 | Antibody variable domains targeting NKG2D receptor |
TW202003561A (en) | 2018-03-13 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1BB (CD137) agonists |
EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
AR114284A1 (en) | 2018-04-13 | 2020-08-12 | Hoffmann La Roche | HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL |
JP7323200B2 (en) | 2018-04-17 | 2023-08-08 | モレキュラー テンプレーツ,インク. | HER2 Targeting Molecules Containing Deimmunized Shiga Toxin A Subunit Scaffolds |
EP3794041B1 (en) | 2018-05-18 | 2023-07-12 | Glycotope GmbH | Anti-muc1 antibody |
JP2021524449A (en) | 2018-05-23 | 2021-09-13 | アーデーセー セラピューティクス ソシエテ アノニム | Molecular adjuvant |
US20210198370A1 (en) * | 2018-05-31 | 2021-07-01 | Board Of Regents, The University Of Texas System | Bi-specific antibodies and use thereof |
KR20210041586A (en) | 2018-08-01 | 2021-04-15 | 세파론, 인코포레이티드 | Anti-CXCR2 antibodies and uses thereof |
RS63865B1 (en) | 2018-10-15 | 2023-01-31 | Hoffmann La Roche | Methods of treating residual breast cancer with trastuzumab emtansine |
WO2020084503A1 (en) | 2018-10-26 | 2020-04-30 | Cadila Healthcare Limited | A composition comprising antibody with reduced level of basic variants thereof |
CN113677403A (en) | 2019-04-12 | 2021-11-19 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules comprising lipocalin muteins |
US20220387618A1 (en) | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
TW202200618A (en) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof |
US20220017637A1 (en) | 2020-06-23 | 2022-01-20 | Hoffmann-La Roche Inc. | Agonistic cd28 antigen binding molecules targeting her2 |
AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
CA3188134A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
KR20230145038A (en) | 2021-02-09 | 2023-10-17 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | Bioactive substance conjugate, method of manufacturing same and use thereof |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
KR20240009486A (en) | 2021-05-19 | 2024-01-22 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | Nitrogen-containing compounds, conjugates containing them, and uses thereof |
CN117616052A (en) | 2021-07-05 | 2024-02-27 | 江苏康宁杰瑞生物制药有限公司 | Antibody drug conjugate and application thereof |
TW202310878A (en) | 2021-07-22 | 2023-03-16 | 大陸商上海森輝醫藥有限公司 | Drug conjugate of eribulin derivative |
WO2023158883A2 (en) * | 2022-02-19 | 2023-08-24 | Salvitus, Inc. | Probiotic vaccines and related methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821337A (en) * | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO2001000238A1 (en) * | 1999-06-25 | 2001-01-04 | Genentech, Inc. | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
EP1308455A2 (en) * | 1998-05-06 | 2003-05-07 | Genentech, Inc. | A composition comprising anti-HER2 antibodies |
WO2003087131A2 (en) * | 2002-04-10 | 2003-10-23 | Genentech, Inc | Anti-her2 antibody variants |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU687346B2 (en) | 1992-06-30 | 1998-02-26 | Oncologix, Inc. | A combination of anti-erbB-2 monoclonal antibodies and method of using |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
ATE163231T1 (en) | 1993-11-23 | 1998-02-15 | Genentech Inc | KINASE RECEPTOR ACTIVATION TEST |
US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
NZ519191A (en) | 1996-10-18 | 2005-04-29 | Univ Texas | Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
EP0852951A1 (en) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
WO1999048527A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
ATE321066T1 (en) | 1998-05-06 | 2006-04-15 | Genentech Inc | ANTI-HER2 ANTIBODY COMPOSITION |
ES2320311T3 (en) | 1999-05-14 | 2009-05-21 | Genentech, Inc. | TREATMENT WITH ANTI-ERBB2 ANTIBODIES. |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
DE60028970T2 (en) | 1999-07-02 | 2007-02-15 | Genentech Inc., San Francisco | AT HER2 BINDING PEPTIDE COMPOUNDS |
ES2330301T3 (en) | 1999-08-27 | 2009-12-09 | Genentech, Inc. | DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES. |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CN102698265A (en) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
PT1585966E (en) | 2002-07-15 | 2012-02-20 | Hoffmann La Roche | Treatment of cancer with the anti-erbb2 antibody rhumab 2c4 |
BR0214242A (en) * | 2002-09-19 | 2004-09-21 | Cristiano Alberto Ribe Santana | Product Carrier Composition |
WO2004048525A2 (en) * | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
JP4969440B2 (en) | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | ErbB antagonist for the treatment of pain |
SV2006002143A (en) * | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
KR20160096228A (en) | 2004-07-22 | 2016-08-12 | 제넨테크, 인크. | Her2 antibody composition |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
ZA200704796B (en) | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
PE20070207A1 (en) | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
KR20090019890A (en) | 2006-06-05 | 2009-02-25 | 제넨테크, 인크. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
EP2441472B1 (en) | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
WO2008109440A2 (en) * | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
TWI472339B (en) * | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
-
2005
- 2005-07-15 KR KR1020167021573A patent/KR20160096228A/en not_active Application Discontinuation
- 2005-07-15 PL PL05818254T patent/PL1771482T3/en unknown
- 2005-07-15 JP JP2007522579A patent/JP2008507520A/en active Pending
- 2005-07-15 CN CN2005800319054A patent/CN101023100B/en active Active
- 2005-07-15 KR KR1020117009515A patent/KR20110050567A/en not_active Application Discontinuation
- 2005-07-15 ES ES05818254.4T patent/ES2521140T3/en active Active
- 2005-07-15 CA CA2574821A patent/CA2574821C/en active Active
- 2005-07-15 MX MX2007000723A patent/MX2007000723A/en active IP Right Grant
- 2005-07-15 RS RSP20140611 patent/RS53594B1/en unknown
- 2005-07-15 KR KR1020107019485A patent/KR20100101023A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020187000071A patent/KR20180004850A/en not_active Application Discontinuation
- 2005-07-15 BR BRPI0513681-4A patent/BRPI0513681A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020157034266A patent/KR20150140417A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020177012110A patent/KR20170054551A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020197008923A patent/KR20190035967A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020197032521A patent/KR20190126461A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020137015103A patent/KR20130079648A/en not_active Application Discontinuation
- 2005-07-15 SI SI200531907T patent/SI1771482T1/en unknown
- 2005-07-15 KR KR1020127000415A patent/KR20120068807A/en not_active Application Discontinuation
- 2005-07-15 UA UAA200701640A patent/UA90480C2/en unknown
- 2005-07-15 US US11/182,908 patent/US7560111B2/en active Active
- 2005-07-15 EP EP05818254.4A patent/EP1771482B1/en active Active
- 2005-07-15 ZA ZA200701234A patent/ZA200701234B/en unknown
- 2005-07-15 RU RU2007106725/13A patent/RU2361880C2/en active Protection Beyond IP Right Term
- 2005-07-15 KR KR1020147003441A patent/KR20140032004A/en not_active Application Discontinuation
- 2005-07-15 PT PT58182544T patent/PT1771482E/en unknown
- 2005-07-15 KR KR1020187022854A patent/KR20180091967A/en not_active Application Discontinuation
- 2005-07-15 DK DK05818254.4T patent/DK1771482T3/en active
- 2005-07-15 NZ NZ552580A patent/NZ552580A/en unknown
- 2005-07-15 AU AU2005287404A patent/AU2005287404B2/en active Active
- 2005-07-15 KR KR1020077004108A patent/KR20070038557A/en not_active Application Discontinuation
- 2005-07-15 KR KR1020157009058A patent/KR20150043558A/en not_active Application Discontinuation
- 2005-07-15 WO PCT/US2005/025084 patent/WO2006033700A2/en active Application Filing
- 2005-07-20 JO JOP/2005/0105A patent/JO2984B1/en active
- 2005-07-21 SV SV2005002174A patent/SV2006002174A/en unknown
- 2005-07-21 PA PA20058639701A patent/PA8639701A1/en unknown
- 2005-07-21 GT GT200500199A patent/GT200500199A/en unknown
- 2005-07-22 PE PE2005000860A patent/PE20060552A1/en not_active Application Discontinuation
- 2005-07-22 CO CO05072439A patent/CO5720212A1/en not_active Application Discontinuation
- 2005-07-22 AR ARP050103045A patent/AR050353A1/en not_active Application Discontinuation
- 2005-07-22 MY MYPI20053385A patent/MY169272A/en unknown
- 2005-07-22 TW TW094125021A patent/TWI369992B/en active
-
2007
- 2007-01-09 IL IL180608A patent/IL180608A0/en unknown
- 2007-01-19 TN TNP2007000020A patent/TNSN07020A1/en unknown
- 2007-02-05 MA MA29655A patent/MA28784B1/en unknown
- 2007-02-16 CR CR8932A patent/CR8932A/en unknown
- 2007-02-16 EC EC2007007261A patent/ECSP077261A/en unknown
- 2007-02-21 NO NO20070989A patent/NO341293B1/en unknown
- 2007-10-05 HK HK07110819.1A patent/HK1102599A1/en unknown
-
2009
- 2009-06-08 US US12/480,013 patent/US7879325B2/en active Active
-
2011
- 2011-01-07 US US12/986,470 patent/US8241630B2/en active Active
- 2011-05-02 JP JP2011103101A patent/JP2011173914A/en active Pending
-
2014
- 2014-07-03 JP JP2014137889A patent/JP2014208685A/en active Pending
- 2014-11-17 HR HRP20141111TT patent/HRP20141111T1/en unknown
-
2015
- 2015-12-15 JP JP2015244120A patent/JP2016104760A/en active Pending
-
2017
- 2017-04-10 JP JP2017077634A patent/JP2017141283A/en active Pending
-
2018
- 2018-04-17 AR ARP180100971A patent/AR111209A2/en not_active Application Discontinuation
- 2018-08-17 JP JP2018153332A patent/JP2018197258A/en active Pending
-
2020
- 2020-01-28 JP JP2020011593A patent/JP2020079254A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821337A (en) * | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
EP1308455A2 (en) * | 1998-05-06 | 2003-05-07 | Genentech, Inc. | A composition comprising anti-HER2 antibodies |
WO2001000238A1 (en) * | 1999-06-25 | 2001-01-04 | Genentech, Inc. | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
WO2003087131A2 (en) * | 2002-04-10 | 2003-10-23 | Genentech, Inc | Anti-her2 antibody variants |
Non-Patent Citations (3)
Title |
---|
NAHTA R ET AL: "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2343 - 2346, XP002378994, ISSN: 0008-5472 * |
SPIRIDON CAMELIA I ET AL: "Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1720 - 1730, XP002389218, ISSN: 1078-0432 * |
VAJDOS F F ET AL: "Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 320, no. 2, 5 July 2002 (2002-07-05), pages 415 - 428, XP004449739, ISSN: 0022-2836 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255149B2 (en) | 2008-05-02 | 2016-02-09 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Cytotoxic immunoglobulin |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006033700A3 (en) | Her2 antibody composition | |
EA200802170A1 (en) | LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY | |
WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
UA104585C2 (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof | |
IL214325A (en) | Anti-cmet antibody, composition comprising it and use thereof | |
WO2006051110A3 (en) | Stable formulations of insulinoptropic peptides | |
IL195338A (en) | Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
WO2006044908A3 (en) | Antibody formulation in histidine-acetate buffer | |
MX2009006594A (en) | Formulations. | |
NO2014009I2 (en) | Compounds, pharmaceutical compositions and uses thereof, and process for the preparation of said compounds | |
WO2007115049A3 (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
WO2002030460A3 (en) | Therapeutic antibodies | |
WO2006059234A3 (en) | Bicyclic amides as kinase inhibitors | |
WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
WO2006007448A3 (en) | Pharmaceutical co-crystal compositions and related methods of use | |
HK1094167A1 (en) | Monoclonal antibodies to hepatocyte growth factor | |
WO2005123043A3 (en) | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same | |
NO20055209D0 (en) | Peptabody for cancer treatment | |
ATE499939T1 (en) | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN POLYMORPHO A | |
WO2006109303A3 (en) | Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them | |
WO2006110185A3 (en) | Antiinfective lipopeptides | |
WO2006047162A3 (en) | Compositions and methods for treatment of disease caused by yersinia spp infection | |
WO2005048822A3 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof | |
WO2005105832A3 (en) | Biologically active peptide vapeehptllteaplnpk derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180608 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552580 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 454/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500171 Country of ref document: PH Ref document number: MX/a/2007/000723 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2574821 Country of ref document: CA Ref document number: 2007522579 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005818254 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701234 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-008932 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005287404 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077004108 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20070174 Country of ref document: BY Ref document number: 2007106725 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005287404 Country of ref document: AU Date of ref document: 20050715 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005287404 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580031905.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077004108 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005818254 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000033 Country of ref document: DZ |
|
WWP | Wipo information: published in national office |
Ref document number: 20070174 Country of ref document: BY |
|
ENP | Entry into the national phase |
Ref document number: PI0513681 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0611 Country of ref document: RS |